Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review

by Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Victoria Alegria, Asher A. Chanan-Khan, Sikander Ailawadhi
Published 2020-01-01

Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.

by Aneel Paulus, Kasyapa S Chitta, Paul K Wallace, Pooja P Advani, Sharoon Akhtar, Maja Kuranz-Blake, Sikander Ailawadhi, Asher A Chanan-Khan
Published 2015-01-01

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

by Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, Jose F. Leis, Saad S. Kenderian, Asher A. Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie L. Fonder, Kristen B. McCullough, Adrienne N. Nedved, Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, Tait D. Shanafelt
Published 2020-05-01

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

by Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos
Published 2020-08-01